186 related articles for article (PubMed ID: 38725027)
21. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rodrigo C; Rajapakse S; Fernando D
Cochrane Database Syst Rev; 2020 Sep; 9(9):CD010458. PubMed ID: 32892362
[TBL] [Abstract][Full Text] [Related]
22. Hemolytic Dynamics of Weekly Primaquine Antirelapse Therapy Among Cambodians With Acute Plasmodium vivax Malaria With or Without Glucose-6-Phosphate Dehydrogenase Deficiency.
Taylor WRJ; Kheng S; Muth S; Tor P; Kim S; Bjorge S; Topps N; Kosal K; Sothea K; Souy P; Char CM; Vanna C; Ly P; Khieu V; Christophel E; Kerleguer A; Pantaleo A; Mukaka M; Menard D; Baird JK
J Infect Dis; 2019 Oct; 220(11):1750-1760. PubMed ID: 31549159
[TBL] [Abstract][Full Text] [Related]
23. Tolerability and safety of weekly primaquine against relapse of Plasmodium vivax in Cambodians with glucose-6-phosphate dehydrogenase deficiency.
Kheng S; Muth S; Taylor WR; Tops N; Kosal K; Sothea K; Souy P; Kim S; Char CM; Vanna C; Ly P; Ringwald P; Khieu V; Kerleguer A; Tor P; Baird JK; Bjorge S; Menard D; Christophel E
BMC Med; 2015 Aug; 13():203. PubMed ID: 26303162
[TBL] [Abstract][Full Text] [Related]
24. Using G6PD tests to enable the safe treatment of Plasmodium vivax infections with primaquine on the Thailand-Myanmar border: A cost-effectiveness analysis.
Devine A; Parmiter M; Chu CS; Bancone G; Nosten F; Price RN; Lubell Y; Yeung S
PLoS Negl Trop Dis; 2017 May; 11(5):e0005602. PubMed ID: 28542194
[TBL] [Abstract][Full Text] [Related]
25. Optimal balance of benefit versus risk for tafenoquine in the treatment of Plasmodium vivax malaria.
Sharma R; Sharma H; Jones S; Borghini-Fuhrer I; Domingo GJ; Gibson RA; Rolfe K; Tan L; Fiţa IG; Chen C; Bird P; Pingle A; Duparc S
Malar J; 2024 May; 23(1):145. PubMed ID: 38741094
[TBL] [Abstract][Full Text] [Related]
26. The reality of using primaquine.
Burgoine KL; Bancone G; Nosten F
Malar J; 2010 Dec; 9():376. PubMed ID: 21184691
[TBL] [Abstract][Full Text] [Related]
27. Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.
Devine A; Battle KE; Meagher N; Howes RE; Dini S; Gething PW; Simpson JA; Price RN; Lubell Y
PLoS Med; 2021 Jun; 18(6):e1003614. PubMed ID: 34061843
[TBL] [Abstract][Full Text] [Related]
28. Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms.
Baird JK; Battle KE; Howes RE
Malar J; 2018 Jan; 17(1):42. PubMed ID: 29357870
[TBL] [Abstract][Full Text] [Related]
29. Weekly primaquine for radical cure of patients with Plasmodium vivax malaria and glucose-6-phosphate dehydrogenase deficiency.
Taylor WRJ; Meagher N; Ley B; Thriemer K; Bancone G; Satyagraha A; Assefa A; Chand K; Chau NH; Dhorda M; Degaga TS; Ekawati LL; Hailu A; Hasanzai MA; Naddim MN; Pasaribu AP; Rahim AG; Sutanto I; Thanh NV; Tuyet-Trinh NT; Waithira N; Woyessa A; Dondorp A; von Seidlein L; Simpson JA; White NJ; Baird JK; Day NP; Price RN
PLoS Negl Trop Dis; 2023 Sep; 17(9):e0011522. PubMed ID: 37672548
[TBL] [Abstract][Full Text] [Related]
30. Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia.
Lo E; Zhong D; Raya B; Pestana K; Koepfli C; Lee MC; Yewhalaw D; Yan G
Malar J; 2019 Oct; 18(1):340. PubMed ID: 31590661
[TBL] [Abstract][Full Text] [Related]
31. G6PD deficiency at Sumba in Eastern Indonesia is prevalent, diverse and severe: implications for primaquine therapy against relapsing Vivax malaria.
Satyagraha AW; Sadhewa A; Baramuli V; Elvira R; Ridenour C; Elyazar I; Noviyanti R; Coutrier FN; Harahap AR; Baird JK
PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003602. PubMed ID: 25746733
[TBL] [Abstract][Full Text] [Related]
32. G6PD deficiency alleles in a malaria-endemic region in the Western Brazilian Amazon.
Dombrowski JG; Souza RM; Curry J; Hinton L; Silva NRM; Grignard L; Gonçalves LA; Gomes AR; Epiphanio S; Drakeley C; Huggett J; Clark TG; Campino S; Marinho CRF
Malar J; 2017 Jun; 16(1):253. PubMed ID: 28619120
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of Plasmodium vivax malaria recurrence in Brazil.
Daher A; Silva JCAL; Stevens A; Marchesini P; Fontes CJ; Ter Kuile FO; Lalloo DG
Malar J; 2019 Jan; 18(1):18. PubMed ID: 30670020
[TBL] [Abstract][Full Text] [Related]
34. Improving the radical cure of vivax malaria (IMPROV): a study protocol for a multicentre randomised, placebo-controlled comparison of short and long course primaquine regimens.
IMPROV Study Group
BMC Infect Dis; 2015 Dec; 15():558. PubMed ID: 26643116
[TBL] [Abstract][Full Text] [Related]
35. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis.
Rajasekhar M; Simpson JA; Ley B; Edler P; Chu CS; Abreha T; Awab GR; Baird JK; Bancone G; Barber BE; Grigg MJ; Hwang J; Karunajeewa H; Lacerda MVG; Ladeia-Andrade S; Llanos-Cuentas A; Pukrittayakamee S; Rijal KR; Saravu K; Sutanto I; Taylor WRJ; Thriemer K; Watson JA; Guerin PJ; White NJ; Price RN; Commons RJ;
Lancet Infect Dis; 2024 Feb; 24(2):184-195. PubMed ID: 37748497
[TBL] [Abstract][Full Text] [Related]
36. Dynamics of G6PD activity in patients receiving weekly primaquine for therapy of Plasmodium vivax malaria.
Taylor WRJ; Kim S; Kheng S; Muth S; Tor P; Christophel E; Mukaka M; Kerleguer A; Luzzatto L; Baird JK; Menard D
PLoS Negl Trop Dis; 2021 Sep; 15(9):e0009690. PubMed ID: 34495956
[TBL] [Abstract][Full Text] [Related]
37. Primaquine treatment and relapse in Plasmodium vivax malaria.
Rishikesh K; Saravu K
Pathog Glob Health; 2016; 110(1):1-8. PubMed ID: 27077309
[TBL] [Abstract][Full Text] [Related]
38. Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health centre, Eastern Ethiopia.
Shenkutie TT; Nega D; Hailu A; Kepple D; Witherspoon L; Lo E; Negash MT; Adamu A; Gebremichael SG; Gidey B; Tasew G; Feleke SM; Kebede T
Malar J; 2022 Sep; 21(1):260. PubMed ID: 36076204
[TBL] [Abstract][Full Text] [Related]
39. Prevalence of G6PD Viangchan variant in malaria endemic areas in Lao PDR: an implication for malaria elimination by 2030.
Ong KIC; Iwagami M; Araki H; Khattignavong P; Soundala P; Keomalaphet S; Prasayasith P; Lorpachan L; Xangsayalath P; Pongvongsa T; Hongvanthong B; Brey PT; Kano S; Jimba M
Malar J; 2019 Mar; 18(1):75. PubMed ID: 30866940
[TBL] [Abstract][Full Text] [Related]
40. G6PD Deficiency and Antimalarial Efficacy for Uncomplicated Malaria in Bangladesh: A Prospective Observational Study.
Ley B; Alam MS; Thriemer K; Hossain MS; Kibria MG; Auburn S; Poirot E; Price RN; Khan WA
PLoS One; 2016; 11(4):e0154015. PubMed ID: 27128675
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
